{'52WeekChange': 1.0174417,
 'SandP52WeekChange': None,
 'address1': 'Bay & Deveaux Streets',
 'address2': '2nd Floor',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 3.36,
 'askSize': 1300,
 'averageDailyVolume10Day': 82700,
 'averageVolume': 252373,
 'averageVolume10days': 82700,
 'beta': 1.689075,
 'beta3Year': None,
 'bid': 3.36,
 'bidSize': 4000,
 'bookValue': 0.02,
 'category': None,
 'circulatingSupply': None,
 'city': 'Nassau',
 'companyOfficers': [],
 'country': 'Bahamas',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 3.5,
 'dayLow': 3.325,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -18.675,
 'enterpriseToRevenue': 2617.533,
 'enterpriseValue': 238195488,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fax': '514 332 2227',
 'fiftyDayAverage': 3.6057143,
 'fiftyTwoWeekHigh': 4.79,
 'fiftyTwoWeekLow': 1.6,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 38530496,
 'forwardEps': None,
 'forwardPE': None,
 'fromCurrency': None,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0.39943,
 'heldPercentInstitutions': 0.02547,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/nymox.com',
 'longBusinessSummary': 'Nymox Pharmaceutical Corporation, a biopharmaceutical '
                        'company, engages in the research and development of '
                        'drugs for the aging population. Its lead drug '
                        'candidate is Fexapotide Triflutate (NX-1207) that has '
                        'completed Phase III clinical trials for the treatment '
                        'of benign prostatic hyperplasia; and is in Phase II '
                        'clinical trial for low grade localized prostate '
                        'cancer, as well as is in preclinical studies for '
                        'hepatocellular carcinoma. The company also develops '
                        'and markets NicAlert and TobacAlert test strips that '
                        'use urine or saliva to detect use of tobacco '
                        'products. In addition, it offers AlzheimAlert, a '
                        'proprietary urine assay that aids physicians in the '
                        "diagnosis of Alzheimer's disease. The company "
                        'operates in Canada, the United States, Europe, and '
                        'internationally. Nymox Pharmaceutical Corporation was '
                        'founded in 1989 and is headquartered in Nassau, '
                        'Bahamas.',
 'longName': 'Nymox Pharmaceutical Corporation',
 'market': 'us_market',
 'marketCap': 240972480,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_389645',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -12907000,
 'nextFiscalYearEnd': 1640908800,
 'open': 3.48,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '800 936 9669',
 'previousClose': 3.47,
 'priceHint': 4,
 'priceToBook': 168,
 'priceToSalesTrailing12Months': 2648.0493,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 3.5,
 'regularMarketDayLow': 3.325,
 'regularMarketOpen': 3.48,
 'regularMarketPreviousClose': 3.47,
 'regularMarketPrice': 3.48,
 'regularMarketVolume': 59343,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 71718000,
 'sharesPercentSharesOut': 0.061,
 'sharesShort': 4373699,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 3180655,
 'shortName': 'Nymox Pharmaceutical Corporatio',
 'shortPercentOfFloat': 0.1118,
 'shortRatio': 8.93,
 'startDate': None,
 'strikePrice': None,
 'symbol': 'NYMX',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -0.191,
 'twoHundredDayAverage': 3.0421584,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': '23edc1cd-e887-3bb0-a634-6c4888614388',
 'volume': 59343,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.nymox.com',
 'yield': None,
 'ytdReturn': None}